- Home
- RDHL vs INDP Comparison
RDHL vs INDP Comparison
Compare RDHL & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- INDP
- Stock Information
- Founded
- RDHL 2009
- INDP 2000
- Country
- RDHL Israel
- INDP United States
- Employees
- RDHL N/A
- INDP N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- INDP Health Care
- Exchange
- RDHL Nasdaq
- INDP Nasdaq
- Market Cap
- RDHL 3.9M
- INDP 4.0M
- IPO Year
- RDHL N/A
- INDP N/A
- Fundamental
- Price
- RDHL $1.57
- INDP $3.55
- Analyst Decision
- RDHL
- INDP Strong Buy
- Analyst Count
- RDHL 0
- INDP 1
- Target Price
- RDHL N/A
- INDP $140.00
- AVG Volume (30 Days)
- RDHL 1.5M
- INDP 536.0K
- Earning Date
- RDHL 09-05-2025
- INDP 11-11-2025
- Dividend Yield
- RDHL N/A
- INDP N/A
- EPS Growth
- RDHL N/A
- INDP N/A
- EPS
- RDHL N/A
- INDP N/A
- Revenue
- RDHL $9,550,000.00
- INDP N/A
- Revenue This Year
- RDHL $381.91
- INDP N/A
- Revenue Next Year
- RDHL N/A
- INDP N/A
- P/E Ratio
- RDHL N/A
- INDP N/A
- Revenue Growth
- RDHL 157.62
- INDP N/A
- 52 Week Low
- RDHL $1.06
- INDP $2.22
- 52 Week High
- RDHL $8.75
- INDP $47.60
- Technical
- Relative Strength Index (RSI)
- RDHL 43.92
- INDP 46.33
- Support Level
- RDHL $1.64
- INDP $3.41
- Resistance Level
- RDHL $1.90
- INDP $4.00
- Average True Range (ATR)
- RDHL 0.16
- INDP 0.49
- MACD
- RDHL -0.03
- INDP 0.03
- Stochastic Oscillator
- RDHL 10.94
- INDP 10.52
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.